ClinicalTrials.gg
CompletedNCT02495168Updated Nov 29, 2019Results posted

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

A Phase 3 interventional study of Generic Budesonide/Formoterol Fumarate Dihydrate and Symbicort® (Budesonide/Formoterol Fumarate Dihydrate) in Asthma, sponsored by Actavis Inc.. Completed at 17 sites in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-11-29.

Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,714
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
9th of 108
1,714 · median 124
Started
2017
with 4 others
Phase 3
51 of 110
3 open now
Registered
81st of 110
by date

Among the 110 studies testing budesonide in Asthma, this one is the 9th largest by enrollment of the 108 interventional ones that give a count, is one of 5 that started in 2017, is one of 51 in phase 3, and was the 81st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

This study has a randomized multiple-dose, placebo-controlled, parallel group design consisting of a 2-week open placebo Run-in Period followed by a 6-week Treatment Period with placebo, test product (budesonide 80 microgram [μg]/formoterol fumarate dihydrate 4.5 μg), or reference product (Symbicort® inhalation aerosol).

Read the detailed description

This is a pivotal trial that will examine the therapeutic equivalence of a new generic fixed-dose combination product containing budesonide 80 μg/formoterol fumarate dihydrate 4.5 μg and reference listed drug (RLD) Symbicort® inhalation aerosol in adult participants with chronic but stable asthma as defined in National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP 3) guidelines. To ensure adequate study sensitivity, the test and reference products should both be statistically superior to placebo (p\<0.05) with regard to the bioequivalent study primary endpoints. Participants will be provided a generic placebo pressurized metered-dose inhaler (pMDI) device for use during the 2-week Run-in Period for device training.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adolescent and adult male or female participants (≥12 and ≤75 years of age).
  2. Female participants must not be lactating or pregnant at Screening, as documented by a negative serum pregnancy test with a minimum sensitivity of 25 international unit/liter (IU/L) or equivalent units of beta-human chorionic gonadotropin (β-hCG) at Screening.
  3. Women of (WOCBP) and female partners (WOCBP) of male participants participating in the study, must commit to consistent and correct use of an acceptable method of (at the Investigator's discretion) throughout the study and for 30 days after study drug discontinuation.
  4. Male participants and male partners of female participants (WOCBP) must commit to consistent and correct use of an acceptable method of birth control (at the Investigator's discretion) throughout the study and for 30 days after the study drug discontinuation.
  5. Diagnosed with asthma as defined by the NAEPP 3 at least 6 months prior to Screening. If the participant is new to the study site, the Investigator must confirm the participant's asthma diagnosis. Acceptable means include either medical records or pharmacy records.
  6. Moderate to severe asthma with a pre-bronchodilator (FEV1) of ≥45% and ≤85% of the predicted normal value during measured at least 6 hours after short-acting β agonist (SABA) and at least 24 hours after the last dose of long-acting β agonist (LABA) at Screening and prior to randomization on Day 1.
  7. Currently non-smoking, negative for urine cotinine at Screening, having not used tobacco products (that is, cigarettes, cigars, pipe tobacco, and electronic cigarettes) within the past year, and had ≤10 pack-years of historical use.
  8. (BMI) between 18 to 40 (inclusive) for participants ≥18 years old. For adolescent participants 12 to 17 years old, BMI between 15 to 40 inclusive (in accordance with the BMI range typical for the age).
  9. ≥15% and ≥0.20 L reversibility of FEV1 within 30 minutes following 360 μg (4 puffs) of albuterol (400 μg salbutamol) inhalation (pMDI). If the participant achieves \<15%, but ≥10% reversibility at the Screening, the site may instruct the participant to hold LABA and/or inhaled (ICS) and return up to 7 days later for a repeat test. Only 1 repeat of the Screening spirometry test (to retest reversibility) is allowed.
  10. Able to perform valid and reproducible spirometry results per American Thoracic Society/European Respiratory Society (ATS/ERS) standards at Screening.
  11. Able to inhale study drug properly.
  12. Willing to discontinue asthma medications (ICS and LABAs) during the Run-in Period and for the remainder of the study.
  13. Able to replace current regularly scheduled SABAs with albuterol/salbutamol inhaler for use only on as needed basis for the duration of the study (participants should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits).
  14. Able to continue the following medications without a significant adjustment of dosage, formulation, dosing interval for the duration of the study, and judged able by the Investigator to withhold them for the specified minimum time intervals prior to each clinic visit, if applicable:

    1. Short-acting forms of theophylline: 12 hours.
    2. Twice-a-day controlled-release forms of theophylline: 24 hours.
    3. Once-a-day controlled-release forms of theophylline: 36 hours.
  15. Able to discontinue the following medications for the specified minimum time intervals prior to the Run-in Period and for the remainder of the study, if applicable:

    1. Oral corticosteroids for 30 days.
    2. Parenteral corticosteroids for 30 days.
    3. Oral (not inhaled) SABAs for 24 hours.
  16. Clinical laboratory tests (clinical chemistry, hematology, and urinalysis) and 12-lead (ECG) conducted at Screening within normal limits or abnormal but not to the Investigator. The should be calculated using Bazett's formula.
  17. Willing to give written /assent, and willing and able to follow the study rules and procedures.
  18. Stable on chronic asthma treatment regimen for at least 4 weeks prior to enrollment.
  19. Ability to perform forced expiratory assessments according to ATS standards.

Randomization eligibility criteria:

  1. Baseline pre-bronchodilator FEV1 should be ≥45% and ≤85% of predicted normal value and not vary by more than ±20% from Screening FEV1 value.
  2. Compliance during the Run-in Period of at least 75% based on electronic Diary entries is required for a participant to qualify for randomization. Compliance with the run-in placebo treatment must be between 75% and 125%.
  3. Documented total asthma symptom score of ≥1 for at least 2 days during the Run-in Period.

Exclusion criteria

Exclusion criteria:

  1. Life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnea, respiratory arrest or hypoxic seizures, asthma-related syncopal episode(s), or hospitalizations within the past year or during the Run-in Period.
  2. Exercise-induced asthma as the only asthma-related diagnosis.
  3. Evidence or history of disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the Investigator would put the participant at risk through study participation or would affect the study analyses if the disease exacerbated during the study. Participants with well-controlled hypertension, diabetes or hypercholesterolemia are not excluded as long as their medication does not interfere with the study.
  4. Any other clinically significant pulmonary disease except for asthma, including (COPD), interstitial lung disease, cystic fibrosis, bronchiectasis, chronic bronchitis, emphysema, active pulmonary tuberculosis, pulmonary carcinoma, pulmonary fibrosis, or pulmonary hypertension. In addition, obstructive sleep apnea warranting a prescription for continuous or biphasic positive airway pressure (continuous positive airway pressure [CPAP] or bilevel positive airway pressure [BiPAP]).
  5. Participants who required systemic (for any reason) within the past 4 weeks.
  6. Participants with to any sympathomimetic drug (for example, formoterol, albuterol/salbutamol, or salmeterol) or any inhaled, intranasal, or systemic corticosteroid therapy.
  7. Participants taking medication(s) (either daily or as needed) with the potential to affect the course of asthma or to interact with sympathomimetic amines, for example:

    1. Oral β-blockers.
    2. Strong cytochrome P450 3A4 inhibitors (for example, ritonavir).
    3. Monoclonal antibodies/Biologic agents which may affect the course of asthma (such as mepolizumab, reslizumab, lebrikizumab, and others).
  8. Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 2 weeks prior to Screening or during the Run-in Period.
  9. Factors (for example, infirmity, disability or geographic location) that the Investigator feels would likely limit the participant's compliance with the study protocol or scheduled clinic visits.
  10. Anti-Immunoglobulin E (IgE) (such as omalizumab) use within the 6 months prior to screening.
  11. History of alcohol or drug abuse within the last 6 months.
  12. A positive urine drug screen at Screening. Exceptions are made for a positive urine drug screen at Screening for opiates or stimulants if there is a documented prescription with supporting medical history and diagnosis, and the Principal Investigator assesses there are no safety concerns with participant participation. Screened participants with a urine drug screen positive for marijuana/tetrahydrocannabinol are not eligible for study participation, without exceptions. Repeat drug screening is not allowed.
  13. Have received any other treatment within 30 days (or within 5 terminal half-lives of the investigational drug whichever is longer) of Screening or plans to receive investigational treatment within 30 days after the study is completed.
  14. Be an Investigator, employee, or otherwise be directly affiliated with the study site, Watson Laboratories Inc. and affiliates, or service provider involved in the study including being an immediate family member of an Investigator or site employee (that is, spouse, parent, child, or sibling), whether biological or legally adopted or in foster care.
  15. Non-compliance with the study requirements, rules, and procedures.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,714 participants (actual)

Study arms

  • Experimental
    Generic Budesonide/Formoterol Fumarate Dihydrate

    After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.

    Drug: Generic Budesonide/Formoterol Fumarate Dihydrate

  • Active comparator
    Symbicort (Budesonide/Formoterol Fumarate Dihydrate)

    After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.

    Drug: Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)

  • Placebo comparator
    Placebo

    After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.

    Drug: Placebo

Interventions

  • DrugGeneric Budesonide/Formoterol Fumarate Dihydrate

    Drug pages: Budesonide · Formoterol

    Oral inhalation, generic formulation of the brand-name product.

  • DrugSymbicort® (Budesonide/Formoterol Fumarate Dihydrate)

    Oral inhalation, brand-name product.

    Also known as: Symbicort Turbohaler®

  • DrugPlacebo

    Oral inhalation, no active ingredient.

06

What researchers measure

Primary outcomes

  1. Equivalence Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV1 Area Under Curve [AUC0-12]) on the First Day of Treatment

    FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Baseline-adjusted area under the serial FEV1-time curve was calculated from Time 0 to 12 hours on the first day of the Treatment Period (Day 1). FEV1 AUC0-12 was calculated from baseline-adjusted values using the linear trapezoidal method. The calculation assumed that at time of dosing (Time 0) the baseline adjusted FEV1 was also 0. The calculation proceeded over all available post-dose FEV1 assessments on Day 1 (including unscheduled time points, if any) using actual elapsed time from dosing. FEV1 baseline defined as the average of predose FEV1 values obtained on Day 1. If some of these values were missing, the average was calculated using the available values, however, a minimum of 2 predose FEV1 values were required; participants who had only 1 or no predose FEV1 measurements on Day 1 would have their FEV1 baseline missing, and the participant was to be excluded from analysis.

    Time frame: 0 to 12 hours on Day 1

  2. Superiority Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV AUC0-12) on the First Day of Treatment

    FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Baseline-adjusted area under the serial FEV1-time curve was calculated from Time 0 to 12 hours on the first day of the Treatment Period (Day 1). FEV1 AUC0-12 was calculated from baseline-adjusted values using the linear trapezoidal method. The calculation assumed that at time of dosing (Time 0) the baseline adjusted FEV1 was also 0. The calculation proceeded over all available post-dose FEV1 assessments on Day 1 (including unscheduled time points, if any) using actual elapsed time from dosing. FEV1 baseline defined as the average of predose FEV1 values obtained on Day 1. If some of these values were missing, the average was calculated using the available values, however, a minimum of 2 predose FEV1 values were required; participants who had only 1 or no predose FEV1 measurements on Day 1 would have their FEV1 baseline missing, and the participant was to be excluded from analysis.

    Time frame: 0 to 12 hours on Day 1

  3. Equivalence Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment

    FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42. If a participant had no predose assessment on Day 42, the average of all available predose assessments on the last day (for example, Early Termination visit \[up to Day 50\]) when at least 1 predose FEV1 assessments was available was imputed, if the participant discontinued due to lack of efficacy, otherwise there was no imputation. Baseline was defined as the average of at least 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: \[FEV1 at end of treatment\] - \[Baseline FEV1\].

    Time frame: Day 1 up to Day 50

  4. Superiority Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment

    FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42. If a participant had no predose assessment on Day 42, the average of all available predose assessments on the last day (for example, Early Termination visit \[up to Day 50\]) when at least 1 predose FEV1 assessments was available was imputed, if the participant discontinued due to lack of efficacy, otherwise there was no imputation. Baseline was defined as the average of at least 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: \[FEV1 at end of treatment\] - \[Baseline FEV1\].

    Time frame: Day 1 up to Day 50

07

Results

Posted Nov 29, 2019

Participant flow

Participant flow — Overall Study
MilestoneGeneric Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)Placebo
Started504516127
Safety population501514126
Modified intent-to-treat population468478111
Day1 per-protocol set (d1pps) population43743799
Day 42 (d42pps) population38238388
Completed466462110
Not completed385417
Withdrew: Other than specified18225
Withdrew: Did not complete final visit on time432
Withdrew: Physician decision110
Withdrew: Lost to follow-up1061
Withdrew: Withdrawal by subject142
Withdrew: Protocol violation0101
Withdrew: Adverse event483
Withdrew: Lack of efficacy003

Outcome measures

PrimaryEquivalence Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV1 Area Under Curve [AUC0-12]) on the First Day of Treatment

FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Baseline-adjusted area under the serial FEV1-time curve was calculated from Time 0 to 12 hours on the first day of the Treatment Period (Day 1). FEV1 AUC0-12 was calculated from baseline-adjusted values using the linear trapezoidal method. The calculation assumed that at time of dosing (Time 0) the baseline adjusted FEV1 was also 0. The calculation proceeded over all available post-dose FEV1 assessments on Day 1 (including unscheduled time points, if any) using actual elapsed time from dosing. FEV1 baseline defined as the average of predose FEV1 values obtained on Day 1. If some of these values were missing, the average was calculated using the available values, however, a minimum of 2 predose FEV1 values were required; participants who had only 1 or no predose FEV1 measurements on Day 1 would have their FEV1 baseline missing, and the participant was to be excluded from analysis.

Time frame:
0 to 12 hours on Day 1
Reported as:
Mean · Liter*hour (Lh)
Equivalence Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV1 Area Under Curve [AUC0-12]) on the First Day of Treatment
Liter*hour (Lh)Generic Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)Placebo
Equivalence Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV1 Area Under Curve [AUC0-12]) on the First Day of Treatment3.637 ± 3.25323.584 ± 2.99131.460 ± 3.3183
Statistical analysis
  • Generic Budesonide/Formoterol Fumarate Dihydrate vs Symbicort (Budesonide/Formoterol Fumarate Dihydrate) · Test/referece ls mean ratio: 101.9 · 90% CI 92.7 to 111.9Fieller's formula was applied to calculate the 90% confidence interval (CI) for the generic budesonide/formoterol fumarate and Symbicort LS mean ratio; covariance between treatment means was assumed to be 0.
PrimarySuperiority Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV AUC0-12) on the First Day of Treatment

FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Baseline-adjusted area under the serial FEV1-time curve was calculated from Time 0 to 12 hours on the first day of the Treatment Period (Day 1). FEV1 AUC0-12 was calculated from baseline-adjusted values using the linear trapezoidal method. The calculation assumed that at time of dosing (Time 0) the baseline adjusted FEV1 was also 0. The calculation proceeded over all available post-dose FEV1 assessments on Day 1 (including unscheduled time points, if any) using actual elapsed time from dosing. FEV1 baseline defined as the average of predose FEV1 values obtained on Day 1. If some of these values were missing, the average was calculated using the available values, however, a minimum of 2 predose FEV1 values were required; participants who had only 1 or no predose FEV1 measurements on Day 1 would have their FEV1 baseline missing, and the participant was to be excluded from analysis.

Time frame:
0 to 12 hours on Day 1
Reported as:
Mean · Lh
Superiority Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV AUC0-12) on the First Day of Treatment
LhGeneric Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)Placebo
Superiority Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV AUC0-12) on the First Day of Treatment3.630 ± 3.25283.573 ± 2.99601.449 ± 3.3033
Statistical analysis
  • Generic Budesonide/Formoterol Fumarate Dihydrate vs Placebo · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 2.334 · 95% CI 1.673 to 2.996
  • Symbicort (Budesonide/Formoterol Fumarate Dihydrate) vs Placebo · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 2.606 · 95% CI 1.939 to 3.273
PrimaryEquivalence Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment

FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42. If a participant had no predose assessment on Day 42, the average of all available predose assessments on the last day (for example, Early Termination visit \[up to Day 50\]) when at least 1 predose FEV1 assessments was available was imputed, if the participant discontinued due to lack of efficacy, otherwise there was no imputation. Baseline was defined as the average of at least 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: \[FEV1 at end of treatment\] - \[Baseline FEV1\].

Time frame:
Day 1 up to Day 50
Reported as:
Mean · liters
Equivalence Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment
litersGeneric Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)Placebo
Equivalence Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment0.278 ± 0.33060.283 ± 0.32410.094 ± 0.3298
Statistical analysis
  • Generic Budesonide/Formoterol Fumarate Dihydrate vs Symbicort (Budesonide/Formoterol Fumarate Dihydrate) · Test/reference ls mean ratio: 99.8 · 90% CI 87.0 to 114.5Fieller's formula was applied to calculate the 90% CI for the generic budesonide/formoterol fumarate and Symbicort LS mean ratio; covariance between treatment means was assumed to be 0.
PrimarySuperiority Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment

FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42. If a participant had no predose assessment on Day 42, the average of all available predose assessments on the last day (for example, Early Termination visit \[up to Day 50\]) when at least 1 predose FEV1 assessments was available was imputed, if the participant discontinued due to lack of efficacy, otherwise there was no imputation. Baseline was defined as the average of at least 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: \[FEV1 at end of treatment\] - \[Baseline FEV1\].

Time frame:
Day 1 up to Day 50
Reported as:
Mean · liters
Superiority Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment
litersGeneric Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)Placebo
Superiority Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment0.269 ± 0.32380.277 ± 0.31560.124 ± 0.3673
Statistical analysis
  • Generic Budesonide/Formoterol Fumarate Dihydrate vs Placebo · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 0.159 · 95% CI 0.093 to 0.226
  • Symbicort (Budesonide/Formoterol Fumarate Dihydrate) vs Placebo · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 0.164 · 95% CI 0.099 to 0.229

Adverse events

Collected over First day of the Treatment Period (Day 1) up to Day 72. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Generic Budesonide/Formoterol Fumarate Dihydrate0/501 (0%)3/501 (0.6%)70/501 (14%)
Symbicort (Budesonide/Formoterol Fumarate Dihydrate)0/514 (0%)2/514 (0.4%)79/514 (15.4%)
Placebo0/126 (0%)1/126 (0.8%)15/126 (11.9%)
Most frequent serious events
Most frequent serious events
EventGeneric Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)Placebo
AnaemiaBlood and lymphatic system disorders0/5010/5141/126
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2990/2920/70
Atrial fibrillationCardiac disorders1/5010/5140/126
Non-cardiac chest painGeneral disorders1/5010/5140/126
Upper respiratory tract infectionInfections and infestations0/5011/5140/126
Hypertensive crisisVascular disorders0/5011/5140/126
Most frequent other events
Showing 10 of 109
Most frequent other events
EventGeneric Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)Placebo
Upper respiratory tract infectionInfections and infestations12/5018/5143/126
HeadacheNervous system disorders5/50111/5143/126
Viral upper respiratory tract infectionInfections and infestations10/5015/5141/126
AsthmaRespiratory, thoracic and mediastinal disorders3/5014/5142/126
Back painMusculoskeletal and connective tissue disorders0/5016/5140/126
SinusitisInfections and infestations0/5015/5141/126
DysphoniaRespiratory, thoracic and mediastinal disorders3/5015/5140/126
GastroenteritisInfections and infestations0/5012/5141/126
HypocalcaemiaMetabolism and nutrition disorders0/5010/5141/126
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/5010/5141/126

Baseline characteristics

Randomized participants who received at least 1 dose of study drug during Treatment Period (Safety Population).

Age, Continuous
Age, Continuous(years)Generic Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)PlaceboTotal
Mean42.7 ± 15.3943.9 ± 15.5641.5 ± 15.8843.1 ± 15.53
Sex: Female, Male
Sex: Female, Male(Participants)Generic Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)PlaceboTotal
Female29929270661
Male20222256480
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Generic Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)PlaceboTotal
Hispanic or Latino17118048399
Not Hispanic or Latino33033478742
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Generic Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)PlaceboTotal
American Indian or Alaska Native0202
Asian911525
Native Hawaiian or Other Pacific Islander0202
Black or African American908623199
White40241097909
More than one race0314
Unknown or Not Reported0000
Forced Expiratory Volume in 1 Second (FEV1)
Forced Expiratory Volume in 1 Second (FEV1)(liters)Generic Budesonide/Formoterol Fumarate DihydrateSymbicort (Budesonide/Formoterol Fumarate Dihydrate)PlaceboTotal
Mean2.113 ± 0.55242.083 ± 0.54002.136 ± 0.59752.102 ± 0.5515
08

Study locations

17 sites
  • Site 100
    Surprise, Arizona, United States
  • Site 101
    Huntington Beach, California, United States
  • 111
    San Jose, California, United States
  • 114
    Centennial, Colorado, United States
  • 104
    Hialeah, Florida, United States
  • 103
    Miami, Florida, United States
  • 105
    Miami, Florida, United States
  • 107
    Miami, Florida, United States
  • 106
    Bozeman, Montana, United States
  • 113
    Bellevue, Nebraska, United States
  • 112
    Cincinnati, Ohio, United States
  • 108
    Edmond, Oklahoma, United States
  • 115
    Eugene, Oregon, United States
  • 116
    Medford, Oregon, United States
  • 110
    Rock Hill, South Carolina, United States
  • 109
    Smyrna, Tennessee, United States
  • 102
    Waco, Texas, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in May 2018, 16 months.

Results were first posted in Nov 2019, 1 year 5 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 16 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2015
First posted
Jul 13, 2015
StartActual
Jan 13, 2017
Primary completionActual
May 31, 2018
CompletionActual
May 31, 2018
Results first posted
Nov 29, 2019
Last update
Nov 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02495168
Lead sponsor
Actavis Inc.
Responsible party
Sponsor
First posted
Jul 13, 2015
Start date
Jan 13, 2017
Primary completion
May 31, 2018
Completion
May 31, 2018
Results posted
Nov 29, 2019
Last update
Nov 29, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion